Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-00184562
- Development stage
- Phase 1
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
PF-00184562 (also referred to as PF-184562 or PF00184562) is an investigational small molecule compound developed by Pfizer. It was studied in a first-in-human, phase 1 clinical trial to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers. The study also compared neuropsychometric and tolerability measures of PF-00184562 with olanzapine. The primary indication explored for this drug was schizophrenia; however, development does not appear to have advanced beyond early clinical trials[1][2][3][4]. Specific details about the mechanism of action or molecular target have not been disclosed in public sources.
Beyond the preview
Go deeper on PF-00184562.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-00184562.